CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
vorinostat +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01153672
NCT01153672N/ACompleted
CompareCT.gov

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy

University of Washington·interventional·Posted Jun 30, 2010·Updated Sep 6, 2019

In Brief

A clinical study evaluating vorinostat, laboratory biomarker analysis, and 7 other interventions for Male Breast Cancer and 2 related conditions. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 30, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2012
Study CompletionAug 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.0 years ago

Interventions

vorinostatdrug

Given PO

laboratory biomarker analysisother

Correlative studies

biopsyprocedure

Optional correlative studies

F-18 16 alpha-fluoroestradiolradiation

Correlative studies

positron emission tomographyprocedure

Correlative studies

anastrozoledrug

Given PO

letrozoledrug

Given PO

exemestanedrug

Given PO

gene expression analysisgenetic

Correlative studies